Integrated approach to antibody discovery
Symphogen generates new therapeutic projects together with disease experts in the Servier Oncology & Neuro Inflammation groups based on either natural antibodies, antibody drug conjugates or antibody scaffolds like bispecifics, etc.
During drug development, we also work closely together with Servier experts within protein sciences, protein modelling or protein structure determination Symphogen has fully developed cell line development and CMC capabilities to ensure well characterized high-quality antibody products for the clinic.
Symplex – a robust antibody discovery platform
The Symplex® technology is our fully integrated approach to antibody discovery. The productivity of our antibody discovery process is evidenced by the size and diversity of the repertoires of high-quality antibodies from multiple species that we have generated straight from animal immunizations, without the need for further time-consuming antibody optimizations.
How can Symplex help in efficient antibody discovery:
- It uses multiple species to overcome target conservation and lack of species cross-reactivity
- Innovative immunization regimens ensure high-affinity antibody responses against difficult targets
- Symplex isolates entire unbiased natural immune responses, and delivers immense target specific repertoires that increase the likelihood of finding antibodies with ultra-rare functional properties
- Fully recombinant approach and full-length antibodies from start to finish enable up front functional screening of unmodified drug candidates in any isotype